Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ovarian tumor antigens.

M D Benson, J R Lurain, M Newton

    The Journal of Reproductive Medicine
    |January 1, 1983
    PubMed
    Summary

    Advances in tumor immunology offer new hope for ovarian cancer diagnosis and therapy. Tumor-associated antigens (TAAs) and monoclonal antibodies show promise for improved detection and treatment strategies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines.

    Therapeutics and clinical risk management·2020
    Same author

    Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial.

    European journal of neurology·2020
    Same author

    Amniotic fluid embolism: Then and now.

    Obstetric medicine·2016
    Same author

    Maternal collapse: Challenging the four-minute rule.

    EBioMedicine·2016
    Same author

    Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials.

    Journal of the neurological sciences·2014
    Same author

    Pulmonary embolism in pregnancy. Consensus and controversies.

    Minerva ginecologica·2012

    Area of Science:

    • Oncology
    • Immunology
    • Biotechnology

    Background:

    • Growing understanding of tumor immunology and tumor-associated antigens (TAAs) presents significant opportunities for ovarian cancer management.
    • Monoclonal antibodies, produced via hybridoma technology, can enhance the specificity of diagnostic assays like radioimmunoassay.
    • Several TAAs are currently utilized for ovarian cancer diagnosis and monitoring, with ongoing research identifying new targets.

    Purpose of the Study:

    • To explore the potential of tumor-associated antigens (TAAs) and monoclonal antibodies in improving ovarian cancer diagnosis and therapy.
    • To highlight the role of hybridoma-produced monoclonal antibodies in enhancing diagnostic specificity for ovarian cancer.
    • To review current and emerging TAAs for ovarian cancer and assess their therapeutic implications.

    Main Methods:

    • Utilizing knowledge of tumor immunology and TAAs.
    • Employing hybridoma-produced monoclonal antibodies for enhanced radioimmunoassay specificity.
    • Reviewing existing literature on TAAs for ovarian cancer diagnosis, follow-up, and therapeutic applications.

    Main Results:

    • Over a dozen TAAs are currently valuable for ovarian cancer diagnosis and follow-up.
    • New TAAs have been recently identified, though none are yet suitable for screening purposes.
    • Successful treatment of mouse ovarian cancer using antibodies against TAAs has been reported.

    Conclusions:

    • Antibody-based therapies targeting TAAs show potential for ovarian cancer treatment.
    • Preliminary studies involving heterologous antibodies to TAAs in ovarian cancer patients indicate minimal toxicity.
    • Antibody-based immunotherapy represents a promising future therapeutic approach for ovarian cancer.

    Related Experiment Videos